Journal: Frontiers in Immunology

Article Title: Fruquintinib saddles tumor immune tolerance by curbing pro-tumoral immature myeloid cell populations

doi: 10.3389/fimmu.2025.1699980

Figure Lengend Snippet: Combinatorial treatment with nab-paclitaxel and fruquintinib enhances the response to single therapy in colon carcinoma models, exhibiting superior myeloid cell depletion compared to nab-paclitaxel alone. (A-B) Evolution of tumor volume (left) and tumor weight (right) of MC38 tumor-bearing mice treated for 13 days with fruquintinib (5 mg/kg/day, orally) and/or nab-paclitaxel (10 mg/kg, intravenous) for a total of five doses (days 0, 2, 5, 7, 9 post-treatment). Data corresponding to a single experiment of n =6–7 mice per group. (B) Quantification by flow cytometry of the frequency of CD4 + and CD8 + T lymphocytes, CD11b + myeloid cells, Ly6C + inflammatory monocytes, CD4 - CD8 - CD11b + CD11c + CDc2 cells, CD4 - CD8 - CD11b - CD11c + plasmacytoid dendritic cells (pDCs), F4/80 + macrophages and, immunosuppressive F4/80 + CD206 + macrophages in mice treated with fruquintinib, nab-paclitaxel or a combination of both as in (A) . (C) Quantification by flow cytometry of podoplanin-positive myeloid cells (CD11b + PDPN + ), macrophages (CD11b + F4/80 + ), CD11b stem cells (CD11b + Sca1 + ), M-LECP (CD11b + PDPN + F4/80 + Sca1 + ) and VEGFR3/FLT4/CD310 expressing macrophages (CD11b + CD310 + , F4/80 + ), in ex vivo differentiated M-LECP from bone marrow-derived cells treated with nab-PTX (30 nM) or nab-PTX + fruquintinib (5 µM), (three independent experiments of n=2 mice per condition). (U, untreated; PTX: Nab-paclitaxel; PTX+F: Nab-paclitaxel and fruquintinib). Data are presented as mean ± SEM. Statistical analyses were performed using one-way ANOVA. * p < 0.05 ** p < 0.01 *** p < 0.001 and **** p < 0.0001.

Article Snippet: Fruquintinib and nab-paclitaxel (nab-PTX) were purchased from MedChemExpress (Madrid, Spain).

Techniques: Flow Cytometry, Expressing, Ex Vivo, Derivative Assay

Journal: Cellular and Molecular Bioengineering

Article Title: Re-engineering Antimicrobial Peptides into Oncolytics Targeting Drug-Resistant Ovarian Cancers

doi: 10.1007/s12195-020-00626-z

Figure Lengend Snippet: Chemotherapeutic synergy. (a) Isobolograms of MAD1 and Doxorubicin (Dox), Paclitaxel (Ptx) or Cisplatin (Cis) combinatorial synergy in OVCAR-3 (left) and NCI/ADR-RES (right) cells. Fractional inhibitory concentration (FIC) < 1 and < 0.5 represent additive and synergistic effects, respectively. (b) Comparison of Dox and Cis IC50 towards NCI/ADR-RES as either a monotherapy (ADR-RES, black) or in combination with 20 μM MAD1 (ADR-RES + MAD1, grey). Activity of each drug as a monotherapy in pre-resistant OVCAR-3 (OVCAR-3, white) cells shown for comparison. (c–f) Indicated ovarian cancer cell line or patient-derived ovarian carcinoma cells were cultured in ultra-low attachment conditions and treated for 48 h with 2 μM cisplatin or 4 μM MAD1 alone and in combination. Data represent volume in arbitrary units (a.u.) and median.

Article Snippet: 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), Fmoc-protected amino acids, N,N 0 -diisopropylcarbodiimide (DIC), O-(7-Azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HATU), N,N -dimethylformamide (DMF), and Paclitaxel were purchased from Chem-Impex International, Inc. RPMI-1640, M199, trypsin and EDTA solution, Antibiotic-Antimycotic Solution, ultra-low attachment (ULA) plates, and 1× phosphate buffered saline (PBS) were purchased from Corning.

Techniques: Concentration Assay, Comparison, Activity Assay, Derivative Assay, Cell Culture

Journal: Cancers

Article Title: Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment

doi: 10.3390/cancers13246239

Figure Lengend Snippet: ( a ) Microtubule-interfering cytotoxic agents used in the treatment of ovarian cancer. ( b ) Evidence for microtubule-interfering cytotoxic agents used in frontline and recurrence treatment of ovarian cancer.

Article Snippet: Nab-paclitaxel obviates the need for Cremophor ® (BASF, Florham Park, NJ, USA) as the vehicle and infusion reactions have not been seen in phase I, II, or III studies [ , , ].

Techniques: Western Blot, Over Expression, Derivative Assay, Activity Assay, Concentration Assay, Modification, Expressing, Binding Assay

Journal: Genes

Article Title: Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities

doi: 10.3390/genes11091098

Figure Lengend Snippet: Landmark clinical trials leading to the current empiric chemotherapy regimens for advanced pancreatic ductal adenocarcinoma (PDAC). * Trial design did not include stratification based on KRAS or EGFR mutational status.

Article Snippet: Von Hoff et al. [ ] MPACT , 2013 , Gemcitabine + Nab-Paclitaxel , Gemcitabine , 8.5 vs. 6.7.

Techniques: Clinical Proteomics

Journal: Genes

Article Title: Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities

doi: 10.3390/genes11091098

Figure Lengend Snippet: Landmark clinical trials leading to the current empiric adjuvant chemotherapy regimens for resected PDAC. mFOLFIRINOX, modified FOLFIRINOX.

Article Snippet: Von Hoff et al. [ ] MPACT , 2013 , Gemcitabine + Nab-Paclitaxel , Gemcitabine , 8.5 vs. 6.7.

Techniques: Clinical Proteomics, Adjuvant, Modification